The main task of the European Research Initiative on Anaplastic Lymphoma kinase (ALK)-related malignancies is to strengthen cooperation and partnership of research groups focused on the role of ALK in cancer.
Our research groupsIn this paper, Hoareau-Aveilla et al show that Anaplastic Large Cell lymphoma resistant to the ALK/cMet inhibitor Crizotinib are sensitive to demethylating agents in part through reactivation of expression of miR150.
Other publications
Interested in joining us? Working on an ALK-related malignancy? We always welcome new members to ERIA!
Contact Suzanne TurnerERIA forms the consortium for the ALKATRAS ITN, which has now recruited 15 young researchers
ERIA continuously reports research findings about ALK-related malignancies in peer reviewed publications. Explore the most recent findings here.
The main task of ERIA is to strengthen cooperation and partnership into ALK related malignancies, which will be achieved through annual conferences.
